A bipartisan group of U.S. lawmakers is investigating hundreds of clinical trials conducted by American drug companies in collaboration with Chinese military-run hospitals. Concerns include potential risks to U.S. intellectual property and ethical issues surrounding trials in regions like Xinjiang. The FDA has until October 1 to respond to lawmakers' inquiries.